Drug Profile
Research programme: cancer therapeutics - Sprint Biosciences/Unknown company
Alternative Names: PIP4K2a inhibitorsLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Sprint Bioscience
- Developer Unknown
- Class Antineoplastics
- Mechanism of Action 1-phosphatidylinositol 4-kinase modulators; Neoplasm protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 07 Jul 2016 Phosphatidylinositol-5-phosphate 4-kinase type-2 alpha inhibitors licensed to an undisclosed US based company worldwide
- 07 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)